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Abstract
Background: miRNAs control important cellular functions including angiogenesis/angiostasis or fibrosis and reveal
altered expression during pathological processes in the lung.
Methods: The aim of the study was to investigate the expression of selected miRNAs (miR-let7f, miR-15b, miR-16,
miR-20a, miR-27b, miR-128a, miR-130a, miR-192 miR-221, miR-222) in patients with pulmonary sarcoidosis (n = 94)
and controls (n = 50). The expression was assessed by q-PCR in BALF cells and peripheral blood lymphocytes (PB
lymphocytes). For statistical analysis, the Kruskal–Wallis test, Mann–Whitney U- test, Neuman–Keuls’ multiple
comparison test, and Spearman’s rank correlation were used.
Results: In BALF cells, significantly higher expression of miR-192 and miR-221 and lower expression of miR-15b
were found in patients than controls. MiR-27b, miR-192 and miR-221 expression was significantly higher in patients
without parenchymal involvement (stages I) than those at stages II-IV. Patients with acute disease demonstrated
significantly higher miR-27b, miR-192 and miR-221 expression than those with insidious onset. For PB lymphocytes,
patients demonstrated significantly greater miR-15b, miR-27b, miR-192, miR-221 and miR-222 expression, but lower
miR-let7f and miR-130a expression, than controls. Stage I patients demonstrated significantly higher miR-16 and
miR-15b expression than those in stages II-IV, and patients with the acute form demonstrated higher miR-130a and
miR-15b expression. In BALF cells, miR-16 and miR-20a expression was significantly higher in patients with lung
volume restriction, and miR-let7f was higher in the PB lymphocytes in patients with obturation. Several correlations
were observed between the pattern of miRNA expression, lung function parameters and selected laboratory
markers.
Conclusion: The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis,
and that some of them might have negative prognostic value.
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Background
Sarcoidosis is a chronic inflammatory granulomatous
disorder of unknown etiology, characterized in the ma-
jority of patients by intrathoracic lymph node enlarge-
ment and parenchymal lung disease, with the possible
involvement of many extrapulmonary organs.
Among many risk factors, genetic susceptibility seems
to be crucial for its development in subjects exposed to
unknown infectious or non-infectious environmental fac-
tors [1, 2]. This genetic predisposition to sarcoidosis is
known to generally concern immunoregulatory genes [3],
genes regulating various aspects of angiogenesis (e.g., cell
proliferation, apoptosis, migration, morphogenesis) and
angiostasis [4, 5] and genes involved in the pathogenesis
of lung fibrosis [1, 6–8].
Recently, microRNAs (miRNAs) have attracted attention
as being involved in many tissue and cell functions [5, 9].
Mature miRNAs act as small negative regulators of gene ex-
pression via reduction of protein translation or degradation
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of mRNA [10]; they are also involved in feedback interac-
tions as crosstalk between many target genes.
Changes in miRNA expression levels may contribute
to various lung pathologies and diseases, including cystic
fibrosis, chronic obstructive pulmonary disease, asthma,
idiopathic pulmonary fibrosis and lung cancer, by target-
ing many important signaling pathways, such as the
TGF-β/SMAD signaling pathway, or by influencing HIF-
1A related genes [9, 11–14].
The number of studies focused on the crosstalk between
miRNAs and the genes involved in the pathogenesis of
sarcoidosis remains limited [15–17]. Therefore, the
present study evaluates the expression pattern of several
miRNAs which target genes involved in proangiogenic or
angiostatic functions and ECM/EMT remodeling. These
are recognized as important processes in the pathogenesis
of sarcoidosis, as they are involved in granulomatous for-
mation, fibrosis, and the inhibition of the migration and
proliferation of endothelial and epithelial cells [2, 4, 5, 18–
21]. The study assesses the expression of miR-let7f, miR-
15b, miR-16, miR-20a, miR-27b, miR-128a, miR-130a,
miR-192, miR-221, and miR-222: miRNAs which target
the VEGF, TFG-B, SMADs, and HIF-1A genes, as well as
others under the control of hypoxia. The analyses were
performed in BALF cells and peripheral blood (PB) lym-
phocytes of sarcoidosis patients, using the qPCR method.
Methods
All patients signed an individual consent form. The
study was approved by the Medical University of Lodz
Ethics Committee (RNN/141/10/KE).
Study group
A total of 94 patients with pulmonary sarcoidosis were re-
cruited into the study. The patients were admitted to the
Department of Pneumology and Allergy, Norbert Barlicki
memorial University Hospital No. 1 in Lodz, during the
years 2010-2014. The diagnosis was made based on
current standards [1, 22]. For each patient, a consistent
clinical and radiological picture of sarcoidosis was con-
firmed, with the presence of non-caseating granuloma in-
dicated in tissue biopsy. The diagnosis was documented
by EBUS-TBNA, bronchial mucosal biopsy, transbronchial
peripheral lung biopsy, mediastinoscopy, or extrathoracic
biopsy (skin, peripheral lymph nodes). No biopsy was ob-
ligatory only in patients with a typical clinico-radiological
picture (bilateral hilar lymph nodes enlargement) and typ-
ical BAL results (increased percentage of lymphocytes with
CD+4/CD+8 > 3.5). Based on their chest X-ray results, pa-
tients were classified into the following radiological sub-
groups: stage I (hilar lymph node enlargement without
signs of parenchymal involvement), stage II (signs of paren-
chymal involvement in addition to hilar lymph node en-
largement), stage III (parenchymal involvement without
visible hilar lymph node enlargement) and IV (signs of irre-
versible extensive lung fibrosis). An independent compari-
son was performed between patients with acute disease
onset (Löfgren syndrome with arthritis, erythema nodosum,
elevated body temperature – with at least two symptoms
present) and patients with insidious disease onset. The clin-
ical and biological characteristics of the study group are
presented Table 1.
The control group consisted of healthy non-smoking
persons, referred for bronchoscopy due to chronic cough
or the presence of undefined changes on a chest X-ray.
If the radiological signs were defined as clinically insig-
nificant changes or artifacts, the patients underwent a
thorough examination and were finally diagnosed either
with idiopathic cough, or as healthy subjects. A group of
50 subjects was included for gene expression analysis in
Table 1 Clinical and biological characteristics of the study patients
Stage I Stages II-IV Acute onset Insidious onset
n = 46 n = 48 n = 42 n = 51
Gender 25 F 21 M 22 F 26 M 22 F 20 M 24 F 27 M
Age 40.06 42.79 37.29 44.65
FEV1, % pred. 94.30 ± 14.62 87.67 ± 17.31 98.18 ± 13.59 85.10 ± 16.10
FVC, % pred. 103.54 ± 13.46 96.55 ± 117.16 107.52 ± 11.56 93.93 ± 16.21
FEV1/FVC 0.76 ± 0.07 0.747 ± 0.070 0.76 ± 0.07 0.74 ± 0.06
DLCOc, % pred. - 90.73 ± 16.16 - 91.63 ± 16.69
BAL-L% 30.58 ± 18.00 29. 45 ±17.08 35.12 ± 16.62 25.79 ± 17.32
BALF CD4+/CD8+ 6.84 ± 4.37 4.29 ± 3.66 7.98 ± 4.31 3.89 ± 3.18
Ca2+S, [mmol/l 2.44 ± 0.09 2.42 ± 0.18 2.41 ± 0.16 2.45 ± 0.13
Ca2 + U, mmol/24 hrs 4.83 ± 2.31 4.44 ± 2.66 4.24 ± 2.54 4.91 ± 2.46
Sarcoidosis patients were grouped according to the absence/presence of lung parenchymal changes on chest X-ray (stage I vs stage II-IV) and clinical phenotype
(acute vs insidious onset). Abbreviations: BAL% broncholaveolar lavage - % of lymphocytes, Ca2+S serum calcium concentration, Ca2+U calcium in 24 hrs urine collection,
DLCOc lung diffusion capacity for carbon monoxide corrected for hemoglobin, FEV1 forced expiratory volume in 1st second of expiration, FVC forced vital capacity. Data
are presented as mean ± standard deviation
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BALF cells while 20 subjects were included for gene ex-
pression analysis in PB lymphocytes.
Bronchoscopy and bronchoalveolar lavage fluid (BALF)
collection
Bronchoscopy was performed with a flexible broncho-
scope (Pentax, Tokyo, Japan) according to Polish Re-
spiratory Society guidelines [23]. Patients optionally
received midanium and atropine before the examination,
and 2 % lidocaine was used as a topical anesthetic. BAL
fluid (BALF) was collected from medial lobe by instilla-
tion and subsequent withdrawal of 4 x 50 ml of 0.9 %
NaCl. The fluid recovery was 52.1 ± 1.2 %. The crude
BALF was filtered through a gauze to clear the thick
mucus and other contaminants, centrifuged, and the pel-
let was suspended in a phosphate buffer. The total num-
ber of non-epithelial cells (total cell count – TCC) was
presented as n x 106. Cytospin slides were prepared and
stained by May-Grünwald-Giemsa stain. The number of
macrophages, lymphocytes, neutrophils, and eosinophils
was calculated under a light microscope and presented
as % of TCC. After the calculations, the fluid was centri-
fuged (10 min at 1200 rpm) and the BALF supernatant
was suspended in around 350 μl RNAlater RNA
Stabilization Reagent (QIAGEN, Hilden, Germany), and
frozen (-80 °C) until further RNA isolation procedures
could be performed. The percentages of the numbers of
macrophages, lymphocytes, neutrophilis and eosinophils
obtained from the BALF are shown in Fig. 1.
Lung function
Spirometry was performed according to the Polish Respira-
tory Society Guidelines [23] with a computer-based spir-
ometer (Jaeger, Dortmund, Germany). Forced vital capacity
(FVC) and forced expiratory volume in 1 s (FEV1) were
measured, and the Tiffenau index (FEV1/FVC) was calcu-
lated. Lung diffusion capacity for carbon monoxide was
measured in patients with lung parenchymal disease only
(stage II-IV) by the single breath method, using a Lungtest
1000 SB (MES, Cracow, Poland) according to ATS/ERS
standards [24]. The values were corrected for the
hemoglobin concentration (DLCOc). All data (except the
Tiffeneau index) was expressed as % of predicted value.
Peripheral blood sample collection
Blood was collected into 5 ml tubes containing EDTA. For
lymphocyte separation, Histopaque-1077 density gradient
cell separation medium (Sigma-Aldrich, Poznan, Poland)
was used according to the manufacturers protocol. The
supernatant was discarded and cells were resuspended in
350 μl RNAlater RNA Stabilization Reagent before being
frozen at -80 °C.
Fig. 1 Graphs presenting the percentage of lymphocytes, neutrophils and eosinophils obtained from BALF
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miRNA expression analysis
RNA isolation was performed using a mirVana™ miRNA
Isolation Kit (Life Technologies, Carlsbad, CA, USA), ac-
cording to the manufacturer’s protocol. The quality and
quantity of isolated RNA was assessed spectrophotomet-
rically (Eppendorf BioPhotometrTM Plus, Eppendorf,
Hamburg, Germany). The purity of total RNA was deter-
mined using RNA Nano Chips LabChipplates (ratio of
16S to 18S fraction) and miRNA was evaluated by auto-
mated electrophoresis using RNA Pico Chips LabChip-
plates in an Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA).
cDNA was transcribed from 100 ng of total RNA using
a TaqMan® MicroRNA Reverse Transcription Kit (Ap-
plied Biosystems, Carlsbad, CA) in a total volume of
12 μl according to the manufacturer’s protocol.
The relative expression of miRNAs was assessed by
qPCR reactions using Custom TaqMan® Array Micro-
RNA Cards (Applied Biosystems, Carlsbad, CA) according
to the manufacturer’s protocol. The following microRNA
probes were used for the study: hsa-let-7f (UGAGGUA
GUAGAUUGUAUAGUU), hsa-miR-15b (UAGCAGCA
CA UCAUGGUUUACA), hsa-miR-16 (UAGCAGCAC
GUAAAUAUUGGCG), hsa-miR-20a (ACUGCAUUAU
GAGCACUUAAAG), hsa-miR-27b (AGAGCUUAGCU
GAUUGGUGA AC), hsa-miR-128 (UCACAGUGAACCG




The PCR mixture contained 0.90 μl RT Product,
56.25 μl TaqMan® Universal Master Mix II, No AmpEr-
ase® UNG (2X) and 55.35 μl Nuclease-free water (Ap-
plied Biosystems, Carlsbad, CA). TaqMan Array card
was centrifuged according to manufactured protocol and
placed in the Applied Biosystems 7900HT Fast Real-
Time PCR System (Applied Biosystems, Carlsbad, CA)
according to manufactured protocol. The expression
levels (RQ values) of the studied miRNA were calculated
using the delta delta CT method, with the adjustment to
the level of 001973 U6 snRNA expression (endogenous
control) and to the expression of the calibrator (Human
Lung Total RNA Ambion®), for which RQ value was
equal to 1.
Statistical analysis
The Kruskal–Wallis test, Mann–Whitney U-test, Neuman–
Keuls’ multiple comparison test, and Spearman’s rank cor-
relation were used to assess the correlations between relative
miRNA expression and sarcoidosis in the patient groups
classified based on radiological examination (stages I vs. II-
IV), acute vs. chronic disease onset, spirometric parameters,
DLCO, serum Ca2+ concentration, Ca2+ loss in urine over
24 h, the percentage of lymphocytes in BAL (BALF%), the
phenotype of BAL immune cells (CD4+/CD8+), age and sex
of patients. P= 0.05 was regarded as the level of statistical
significance (StatSoft, Cracow, Poland).
Results
Relative expression levels of the studied miRNAs in
sarcoidosis patients vs. controls
BALF cells
The Mann-Whitney U-test revealed significantly greater
miRNA expression in sarcoidosis patients miR-192 (P =
0.00004, Mann-Whitney U- test) and for miR-221 (P =
0.0002, Mann-Whitney U- test) (see Fig. 2). Conversely,
significantly greater miR-15b expression was noted in the
control group (P = 0.04, Mann-Whitney U- test).
No statistically significant differences were observed
between patients and controls for the remaining
analyzed miRNAs (P > 0.05, Mann-Whitney U- test) (see
Additional file 1: Figure S1).
Peripheral blood (PB) lymphocytes
Statistically significant differences (Mann-Whitney
U- test) between patients and controls were observed for
Fig. 2 Box and whisker plots, presenting a) miR-192 b) miR-221 c) miR-15b expression mean values in BALF cells of patients and controls (P = 0.00004,
Mann-Whitney U- test)
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miR-15b (P = 0.00009, Mann-Whitney U- test), miR-27b
(P = 0.01, Mann-Whitney U- test), miR-192 (P = 0.005,
Mann-Whitney U- test), miR-221 (P, Mann-Whitney U-
test), and miR-222 (P = 0.0061, Mann-Whitney U- test)
with higher miRNA expression levels in sarcoidosis pa-
tients. Statistically significant differences (Mann-Whitney
U- test) were also found for miR-let7f (P = 0.00004,
Mann-Whitney U- test), and miR-130a (P = 0.02, Mann-
Whitney U- test), with higher miRNA expression levels in
the control group (see Fig. 3).
No statistically significant differences were found between
patients and controls for the rest of analyzed miRNAs
(P > 0.05, Mann-Whitney U- test) (see Additional file
2: Figure S2).
Relative expression of the studied miRNAs in sarcoidosis
patients according to clinical and radiological
classification
BALF cells
In patients with radiological stage I, miR-192 demon-
strated the greatest mean expression of the evaluated
miRNAs (mean RQ = 12.03) and miR-130a the lowest
(mean RQ = 0.907). In patients with radiological stages
II-IV, the highest mean expression was associated with
miR-let7f (mean RQ = 7.92) and the lowest with miR-
130a (mean RQ = 0.343). In the acute form of disease, as
with radiological stage I, miR-192 demonstrated the great-
est mean expression (mean RQ= 12.099) and miR-130a
the lowest (mean RQ= 0.637). Finally, in the insidious
form of the disease, miR-222 demonstrated the highest
mean expression (mean RQ= 8.600) and miR-130a the
lowest (mean RQ= 0.615) (see Fig. 4).
The expression of miR-130a was decreased in the ma-
jority of studied samples (86–96 %), and the expression
of miR-192 was increased in the majority of studied
samples (74-91 %), regardless the of the clinical disease
classification of the group.
Significantly greater miRNA expression was observed
in patients without parenchymal involvement (stages I)
than those with involvement (Stages II-IV) for miR-27b
(P = 0.04), miR-192 (P = 0.02, Mann-Whitney U- test)
and for miR-221 (P = 0.03, Mann-Whitney U- test) (see
Additional file 3: Figure S3).
Additionally, significantly higher miRNA expression
was found in patients with the acute form of disease
for miR-27b (P = 0.002, Mann-Whitney U- test), miR-
192 (P = 0.01, Mann-Whitney U- test), and miR-221
(P = 0.02, Mann-Whitney U- test) (see Additional file
4: Figure S4).
No statistically significant differences were observed in
the expression of the studied miRNAs in BALF cells for pa-
tients with normal and abnormal spirometry results (P >
0.05, Mann-Whitney U- test) (see Additional file 5: Figure
S5). However, the expression of miRNA-16 and miRNA-
20a in BALF cells was found to be significantly elevated in
the subgroup of patients with a restrictive spirometric pat-
tern (P = 0.009 and P = 0.04, respectively, Mann-Whitney
U- test, see Fig. 5 and Additional file 6: Figure S6).
PB lymphocytes
In patients with radiological stage I, miR-15b was found
to have the highest mean expression of the observed
miRNAs (mean RQ = 28.52) and miR-20a the lowest
(mean RQ = 1.057). In patients with radiological stages
Fig. 3 Box and whisker plots, presenting a) miR-15b b)miR-27b c) miR-192 d) miR-221 e) miR-222 f) miR-letf7 g) miR-130a expression (mean
values) in the PB lymphocytes of patients and controls (P = 0.0002, Mann-Whitney U- test)
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II-IV, miR-221 demonstrated the highest mean expres-
sion (mean RQ = 11.5840) and miR-130a the lowest
(mean RQ = 1.081).
In the acute onset group, miR-15b was the highest
(mean RQ = 26.61) and miR-27b the lowest (mean RQ =
1.478), while in the insidious onset group, miR-221 dem-
onstrated the greatest expression (mean RQ = 14.267)
and miR-130a the lowest (mean RQ =0.670) (see Fig. 6).
The expression of miR-221 was elevated in the major-
ity of studied samples (89–100 %), while that of miR-
Fig. 4 Relative expression (mean RQ values) of the studied miRNAs in sarcoidosis patients according to the clinical and radiological classification
in BALF cells
Fig. 5 Box-and-whisker plots representing the expression of a) miR-16 in BALF cells (P = 0.009; Mann-Whitney U- test) in patients with normal spirometry
and with lung volume restriction, b) miR-20a in BALF cells (P = 0.04; Mann-Whitney U- test) in patients with normal spirometry and in patients with lung
volume restriction
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130a was decreased (50-78 %), regardless of the clinical
disease classification.
Significantly higher expression of miRNA-16 (P = 0.05,
Mann-Whitney U- test) and miR-15b (P = 0.001, Mann-
Whitney U- test) was observed in patients without par-
enchymal involvement (see Additional file 7: Figure S7),
while miRNA-130a (P = 0.04, Mann-Whitney U – test)
and miR-15b (P = 0.004, Mann-Whitney U- test) demon-
strated higher expression in patients with the acute form
of disease (see Additional file 8: Figure S8). Add-
itionally, significantly increased expression of
miRNA-let7f was found in the subgroup of patients
with obturation (P = 0.001, Mann-Whitney U- test)
(see Additional file 9: Figure S9).
Relative expression levels of the studied miRNAs in
relation to patient gender, age, selected biochemical
markers, immunological phenotype and lung function
test parameters
BALF cells
Several correlations were found between miRNA expres-
sion levels and lung function test results, as well as with
selected laboratory markers in sarcoidosis patients (see
Table 2). No statistically significant correlations were
found between miRNA expression and gender (P > 0.05,
Mann-Whitney U-test).
PB lymphocytes
Significantly higher expression of miRNA-let7f was ob-
served in men with chronic form of disease (P = 0.03, U
Mann-Whitney test). Correlations between miRNA ex-
pression level and age, immunological phenotype, lung
function test parameters, and selected laboratory markers
in sarcoidosis patients are shown in Table 2.
Relative expression levels of the studied miRNAs: BALF
cells vs PB lymphocytes in sarcoidosis patients
The majority of studied BALF cell samples demonstrated
higher expression of miR-let-7f, miR-16, miR-192, miR-
222, but lower expression of miR-15b, miR-20a, miR-27b,
miR-128, miR-130, miR-221 compared to PB lymphocytes,
regardless of the clinical disease classification groups.
Only two of the studied miRNAs, miR-16 and miR-
128a, demonstrated overlapping patterns in BALF cells
and PB lymphocytes (see Fig. 7)
However, statistically significant differences between
BALF cells and PB lymphocytes were only observed for
three of the non-overlapping miRNAs: for miRNA-15b
(P = 0.00001, Mann-Whitney U- test) and miRNA-130a
(P = 0.000012, Mann-Whitney U- test), with higher ex-
pression in PB lymphocytes, and for miRNA-let7f, with
higher expression levels in BALF cells (P = 0.000003,
Mann-Whitney U- test).
Fig. 6 Relative expression (mean RQ values) of the studied miRNAs in sarcoidosis patients according to the clinical and radiological classification
in PB lymphocytes
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Discussion
Recent studies have found non-coding regulatory RNAs
to play significant roles in the direct regulation of many
genes and signaling pathways, as well as other miRNAs
[5, 9, 24–26]. However, their biological role is not fully
understood. Previous studies regarding miRNA interac-
tions in the lung have mainly focused on the control of
innate and adaptive lung inflammation [17, 27, 28], pul-
monary fibrosis (IPF, idiopathic pulmonary fibrosis) and
the regulation of extracellular matrix (ECM) remodeling
[16, 29, 30]. Few studies examine miRNA expression in
the course of sarcoidosis [17, 31], and the results which
have been obtained are controversial. Therefore, our
study offers an innovative and valuable insight into the
area, not only because it addresses miRNA expression
levels in the peripheral circulation, but it also attempts
to determine their value in the clinical classification and
monitoring of sarcoidosis patients.
Our findings are difficult to compare with those of
other studies, as they use a range of biological materials
to investigate the studied miRNAs. In addition, the ex-
amined miRNAs may vary with regard to their origin
(free circulating miRNA or exosomal miRNA), profile
and concentration. Studies on pulmonary sarcoidosis
have used different classes of miRNAs and diverse bio-
logical material for miRNA isolation (BALF cells, periph-
eral blood mononuclear cells and serum) [17, 31]. The
most recent studies, by Qazi et al [32] and Ho et al. [33],
suggest that exosomes may be suitable for miRNA as-
sessment in sarcoidosis. They note the presence of an el-
evated level of exosomes in BALF from sarcoidosis
patients and suggest that exosomes may contribute to
the inflammatory state of sarcoidosis via stimulation of
cytokine production from peripheral mononuclear cells.
On the other hand, exosome production is common in
various cells and the mechanisms by which they control
the inflammatory process are not fully understood, as
well as the biological functions of miRNAs derived from
the exosomes.
As miRNAs play a role in cellular communication, the
most beneficial approach would be to assess their role in
a particular signaling pathway which is important in sar-
coidosis, irrespective of their varied origins. It should be
emphasized that microarray-based studies have con-
firmed that alterations in miRNA expression influence
the pathogenesis of sarcoidosis, as well as its relationship
with the TGF-β and WNT/β-catenin signaling pathways
[31]. Therefore, for the purposes of the present study,
several novel miRNAs were chosen which were highly
complementary to genes involved in TGF-β/Smad (regu-
lation of fibrosis) and HIF-1A/VEGF/ING-4 (angiogen-
esis/angiostasis homeostasis) signaling. This choice was
based on their being awarded high target scores accord-
ing to the miRDB database.
The present study focuses on these two pathways be-
cause an important pathogenic component of sarcoidosis
is pulmonary fibrosis, a condition associated with chronic
inflammation, whose symptoms are known to be impaired
wound healing and angiogenesis. Our earlier study assesses
the expression of genes involved in these two pathways,
i.e. the regulation of fibrosis and angiogenetic/angiostatic
homeostasis, in patients with sarcoidosis [6, 34]. Our find-
ings reveal statistically significant correlations between the
expression of some of the studied miRNAs and the expres-
sion of genes which had been studied earlier [6, 34].
The present study compares the expression of selected
miRNAs in PB lymphocytes and BALF cells to analyze
their usefulness as specific systemic and/or local sarcoid-
osis markers. Although significant differences were
found between patients and controls regarding the ex-
pression of several examined miRNAs in PB lympho-
cytes (miR-15b, miR-27b, miR-192, miR-221, miR-222,
Table 2 Significant correlations found in the BALF cells and PB
lymphocytes of sarcoidosis patients



























FEV1 miR-20a Acute onset -0.36 0.03
Ca2+U miR-128a Acute onset -0.49 0.03
PB
lymphocytes












Abbreviations: BAL bronchoalveolar lavage, Ca2+S serum calcium
concentration, Ca2+U calcium in 24 hrs urine collection, DLCOc lung diffusion
capacity for carbon monoxide corrected for hemoglobin, FEV1 forced
expiratory volume in 1st second of expiration, FVC forced vital capacity, PB
peripheral blood; P-values of <0.05 were considered statistically significant
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miR-130a, miR-let-7f ), only three miRNAs were found
to differ in BALF cells (miR-15b, miR-192, and miR-
221). Our findings suggest that the above-mentioned
miRNAs may be vital molecular markers for the disease,
and merit further examination. It should be pointed that
the biomarkers found in BALF cells appear to have high
diagnostic and/or prognostic value, and may also con-
firm the specificity of changes in miRNA expression oc-
curring in response to the lung microenvironment
modifications which take place during sarcoidosis. We
believe that of the two examined cell types, miRNA ana-
lysis may have the highest diagnostic value when per-
formed in BALF cells. Moreover, it is interesting that the
expression patterns of two studied miRNAs, miR-16 and
miR-128a, overlapped in the BALF cells and PB lympho-
cytes of sarcoidosis patients, and their expression was
higher in patients than in controls (see Fig. 5).
It is commonly known that increases in the numbers
of T-cells induced by chemokines secreted by macro-
phages and epithelial cells, as well as shifts in the Th1/
Th2 balance, play crucial roles in the course of sarcoid-
osis. A recent report by Barczyk et al. [35] demonstrates
that CCL4 is highly expressed in T-cells (especially in
CD8+, less so in CD4+) and may serve to recruit new T
cells to the site of inflammation. As a prolonged state of
macrophage activation and CD4+ T-lymphocyte accu-
mulation in the presence of chronic antigenic stimula-
tion is known to lead to inflammation in the early stage
of sarcoidosis, “early sarcoid reaction” [36] and granu-
loma formation, an earlier study by Jazwa et al evaluated
the expression of miR-15b and miR-16 as important
regulators of CD4+ T cells [17]. Based on clinical and
radiological classifications, significant overexpression of
miR-15b and miR-16 in PB lymphocytes was observed in
patients with stage I disease and in patients with the
acute form of the disease. A negative correlation was
also found between miR-16 expression and a lung func-
tion parameter (FEV1/FVC), and significantly higher
miR-16 expression was observed in patients with lung
volume restriction. The results suggest that miR-15b and
miR-16 may be potentially useful prognostic markers in
relation to disease progression and worse prognosis.
Therefore, the influence of both miRNAs on VEGF, a
target gene in angiogenesis and an inflammatory cascade
regulator in sarcoidosis, seems to be pivotal in sarcoid-
osis pathogenesis, regarding the hypoxia-angiogenesis
process and chronic inflammation in early stages of the
disease, as emphasized in previous studies [37, 38]. Our
previous study also confirmed the significant role played
by the up-regulation of VEGF mRNA in sarcoidosis [34].
However, our results regarding miR-15b and miR-16
are not in line with those of Jazwa et al. [17], who did
not report any statistically significant differences be-
tween patients and healthy controls with regard to the
expression of these miRNAs.
Our present study also evaluates the expression of
miR-let7f. This miRNA belongs to the class that targets
TGF-β [39], a key cytokine responsible for lung fibrosis
and epithelial-mesenchymal transition (EMT) [40–42]. It
has been confirmed that in the lung tissue, miR-let7 influ-
ences the epithelial expression of mesenchymal markers
and deposition of collagen without additional injury,
Fig. 7 The expression pattern of miRNAs (mean RQ value) in BALF cells and PB lymphocytes in the sarcoidosis patient group
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which may suggest that the dysregulation of miR-let7 can
lead to the overexpression of crucial pro-fibrotic factors
and may be involved in the pathogenesis of pulmonary fi-
brosis [13, 43, 44]. Our findings reveal increased miR-let7f
expression in BALF cells in patients, and a positive correl-
ation between miR-let7f expression and Ca2 +U in the PB
lymphocytes of the insidious onset group of patients. Ac-
cording to RTG staging (I, II-IV), the greatest mean expres-
sion of miR-let7f was observed during RTG stages II-IV.
As calcium metabolism dysregulation occurs in the course
of sarcoidosis and the presence of hypercalciuria and hy-
percalcemia in 20-50 % of patients [45], miR-let7f up-
regulation may be a valuable marker in the prediction of
calcium metabolism dysregulation during sarcoidosis.
To the best of our knowledge, this is the first study to
examine the expression of miR-20a and miR-27b in sar-
coidosis. Nevertheless, it has already been recognized
that the miR-17 ~ 92 cluster, encoding six different miR-
NAs, is decreased in patients with IPF [46]. In the case
of miR-20a and miR-27b, both are recognized as import-
ant regulators of the TGF-β/Smad pathway and fibrosis
in the lung, with miR-20a additionally targeting VEGF
[47]. In the present study, miR-27b expression was
found to be increased in the PB lymphocytes of sarcoid-
osis patients, but this level was significantly lower in the
advanced stages of the disease (RTG stage II-IV) than in
RTG stage I. Our findings may suggest that miRNA-27b in-
hibition takes place during disease progression. This
miRNA has been shown to play a regulatory role in pro-
fibrotic changes in pulmonary cells in response to TGF-β
signaling [48]. In addition, reductions in miR-27b ex-
pression were also found to be associated with TGF-β
stimulation [48].
In the present study, interesting results were obtained
in the case of miR 192, which showed significant up-
regulation in both BALF cells and PB lymphocytes.
However, its expression was found to be significantly re-
duced during disease progression (in stage II-IV), which
is consistent with the results obtained by Hong et al.
[49], who confirmed the reduction of miR 192 expres-
sion via TGF-β/Smad3 interaction in a study on chronic
renal fibrosis [49].
In conclusion, the data presented in this study indicate
that selected miRNA may enable patients with sarcoid-
osis to be distinguished from potentially healthy con-
trols, based on the different expression profiles of the
two groups (see Fig. 8).
Conclusion
The results of this study indicate that the expression
profiles of selected miRNA allow patients with sarcoid-
osis to be distinguished from potentially healthy con-
trols. Moreover, it should be emphasized that some of
these miRNAs may be themselves recognized as markers
of disease progression, due to their elevated expression
in patients with lung volume restriction or obturation.
The deregulated miRNA expression observed in this
study may play a vital role in the pathogenesis of sar-
coidosis. In particular, the observed significant up-
regulation of the miRNAs involved in angiogenesis
Fig. 8 The differences in miRNA expression profiles (in BALF cells and PB lymphocytes) between controls and patients with sarcoidosis
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(miR-192, miR-221, miR-222) or EMT control (miR-192,
miR-221) may indicate the presence of a significant rela-
tionship between the two processes, and may suggest
that they may play a role in the pathogenesis of the dis-
ease. The obtained results highlight distinct patterns of
miRNA expression in BALF cells and PB lymphocytes in
sarcoidosis patients, indicating the importance of the
lung microenvironment in the modulation of their ex-
pression. However, further studies are needed on larger
groups of patients to develop our findings concerning
these selected miRNAs and gain a greater understanding
of their importance as clinical markers for disease moni-
toring and making therapeutic decisions.
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